NCT02960997View on ClinicalTrials.gov

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 14, 2018

Study Completion Date

December 1, 2021

Conditions
Epidermolysis Bullosa SimplexEpidermolysis Bullosa Simplex KobnerWeber-Cockayne Syndrome
Interventions
DRUG

Sirolimus, 2%

DRUG

Vehicle

Trial Locations (1)

94304

Stanford University, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT02960997 - Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | Biotech Hunter | Biotech Hunter